PHIA Koninklijke Philips N.V.

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations

October 19, 2023

Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – Tampere University Hospital’s (Finland) environmental sustainability, including a deep assessment of the interventional cardiology space and evaluation of its carbon footprint. The results of the analysis have been translated into a joint action plan that will help Heart Hospital accelerate its decarbonization efforts in line with Finland’s world-leading commitment to reach net zero emissions by 2035.

“Sustainability is an integral part of Tampere Heart Hospital strategy. We are aware that hospitals generate a significant amount of waste daily and consume a lot of energy. We want to contribute to the development of environmental responsibility in healthcare,” said Pasi Lehto CEO and Chief Medical Officer at Heart Hospital.

“We want to ascertain where we are now and how we can further accelerate our transition towards net zero,” said Aki Haukilahti, CFO at Tampere Heart Hospital. “Our long-standing relationship with Philips and their industry leadership in driving sustainable healthcare made them a natural partner to help audit our emissions and develop a roadmap for the future.”

Part of an existing 15-year strategic managed services agreement between Heart Hospital and Philips, the analysis involved a detailed lifecycle assessment of the hospital’s medical equipment, supply chain, and clinical operations. The analysis provided a baseline carbon footprint for Tampere Heart Hospital’s interventional cardiology service and facilitated the identification of opportunities to enhance patient throughput and equipment utilization to reduce future emissions. Top findings included optimization of the hospital’s patient care pathways to improve efficiency and materials use, and opportunities for reducing inbound airfreight, reducing waste and improving waste separation. 

“At Philips, we are committed to driving systemic change towards more sustainable and equitable patient care. Through our healthcare technology and expertise, we can help healthcare providers to support their patients with as little impact on the environment as possible,” said Robert Metzke, Global Head of Sustainability at Philips. “This valuable and informative analysis with Tampere Heart Hospital, a pioneering and leading global cardiac care provider, will help achieve our shared goal of taking care of patients and the planet at the same time.”  

In addition to a detailed analysis of carbon emissions associated with the hospital’s medical equipment and supply chain, Philips’ analysis of the hospital’s current emissions also encompasses clinical operations in key patient care pathways.

This sustainability program with Tampere Heart Hospital follows similar analyses conducted by Philips earlier in 2023 at (Nashville, USA) and the private biomedical research and clinical care provider (Lisbon, Portugal), aimed at reducing the carbon footprint of their diagnostic imaging.

Globally, healthcare systems have a significant climate footprint and make a major contribution to the climate crisis [1]. Building on decades of experience reducing energy consumption, waste, and materials and substance usage, Philips has operated globally carbon-neutral since 2020, embedding EcoDesign principles and circular business models into . The company offers a range of health technologies and innovations that help reduce healthcare providers’ impact on the environment. For example, its uses 62.5% less energy [2], and the , which uses a breakthrough design where the magnetic components are completely sealed and only need seven liters of helium over its lifetime compared to roughly 1,500 liters with other Philips systems [3]. Additionally, with , the Ingenia Ambition 1.5T uses up to 53% less power per patient scan [3].

on how Philips is partnering with hospitals around the world to drive sustainable healthcare.

[1]

[2] When compared to an equivalent CT model of one of the industry leaders

[3] Applicable to Ambition S. Philips SmartSpeed power consumption versus Philips SENSE based scanning. Based on COCIR and in-house simulated environment. Results can vary based on site conditions.

For further information, please contact:

Joost Maltha 

Philips Global Press Office 

Tel: +31 6 10 55 8116  

Email: 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachment



EN
19/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips and Masimo announce innovation partnership to advance access t...

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies September 11, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and (NASDAQ: MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-...

 PRESS RELEASE

Philips launches smart telemetry platform for cardiac monitoring that ...

Philips launches smart telemetry platform for cardiac monitoring that provides continuous, enterprise-wide connectivity beyond the bedside September 4, 2025 Empowering clinical teams to respond to surges, track usage and ease workflows with user-friendly touchscreen technology for telemetry patients on the move Cambridge, Massachusetts – , a global leader in health technology, today announced the introduction of an  designed to help address critical challenges in healthcare – including staff shortages and alarm management. A key component of the solution is the next-generation Telemetry M...

 PRESS RELEASE

Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, deliver...

Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, delivering breakthrough image quality and FDA-cleared AI enhancements in cardiovascular ultrasound August 27, 2025  Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac care Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the release of Transcend Plus, the next generation its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. Transcend Plus delivers major advancements in image qua...

Marc Hesselink ... (+3)
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Philips/Volatile results/HOLD

Philips reported a better-than-expected 2Q25 update. We increase our target price to €23 per share (from €21) but keep our Hold rating. The results are surprisingly volatile in our view with large quarterly fluctuations. We believe valuation is fair relative to peers given its lower growth and margin profile.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch